

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No: (CAM:	11874-016-999 417451-999016) IDX 1017

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application Nos. 11/005,443 and 11/516,928 (the "reference applications"). The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patents granted on the reference applications.

The owners further agree that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patents granted on the reference applications in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Ownership of the above-identified application and the reference applications in Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel 021819 frame 0149; and the assignment attached hereto.

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Università Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.

Date: March 30, 2001

By: 

Name: Jean - Pierre Sommadossi

Position: Chief Executive Officer

Università Degli Studi di Cagliari

Date: _____

By: _____

Name: _____

Position: _____

Centre National de la Recherche Scientifique

Date: _____

By: _____

Name: _____

Position: _____

L' Université Montpellier II

Date: _____

By: _____

Name: _____

Position: _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No: (CAM:	11874-016-999 417451-999016) IDX 1017

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Università Degli Studi di Cagliari, Centre National de la Recherche Scientifique and I, Université Montpellier II (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application Nos. 11/005,443 and 11/516,928 (the "reference applications"). The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patents granted on the reference applications.

The owners further agree that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patents granted on the reference applications in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Ownership of the above-identified application and the reference applications in Idenix Pharmaceuticals, Inc., Università Degli Studi di Cagliari, Centre National de la Recherche Scientifique and I, Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel 021819 frame 0149; and the assignment attached hereto.

LAI-2987136v2

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Università Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.


Date: _____ By: _____

Name:

Position:

Università Degli Studi di Cagliari

Date: 23.03.2009

By: 

Name:

IL RETTORE

Position:

(Pasquale Miatretta)



Centre National de la Recherche Scientifique

Date: _____ By: _____

Name:

Position:

L' Université Montpellier II

Date: _____ By: _____

Name:

Position:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No:	11874-016-999
		(CAM:	417451-999016)
			IDX 1017

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Università Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application Nos. 11/005,443 and 11/516,928 (the "reference applications"). The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patents granted on the reference applications.

The owners further agree that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patents granted on the reference applications in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Ownership of the above-identified application and the reference applications in Idenix Pharmaceuticals, Inc., Università Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel 021819 frame 0149; and the assignment attached hereto.

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Università Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.

Date: _____ By: _____

Name:

Position:

Università Degli Studi di Cagliari

Date: _____ By: _____

Name:

Position:

Centre National de la Recherche Scientifique

Date: 30 MARS 2009 By: _____

Directeur de la Politique Industrielle

Name:

Position:

Marc J. LEDOUX

L' Université Montpellier II

Date: _____ By: _____

Name:

Position:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No:	11874-016-999 (CAM: 417451-999016) IDX 1017

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application Nos. 11/005,443 and 11/516,928 (the "reference applications"). The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patents granted on the reference applications.

The owners further agree that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patents granted on the reference applications in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Ownership of the above-identified application and the reference applications in Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; November 11, 2008 at reel 021819 frame 0149; and the assignment attached hereto.

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique and L' Université Montpellier II.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.

Date: _____ By: _____

Name:

Position:

Universita Degli Studi di Cagliari

Date: _____ By: _____

Name:

Position:

Centre National de la Recherche Scientifique

Date: _____ By: _____

Name:

Position:

L' Université Montpellier II

Date: 15/03/2009 By: _____

Name: *Dr. Dorel HERNANDEZ*

Position: *Président*



PATENT ASSIGNMENT AGREEMENT

THIS PATENT ASSIGNMENT AGREEMENT (this "*Assignment*"), effective as of March 4, 2009 (the "*Effective Date*"), is made by and among Idenix Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware, USA ("*Idenix USA*"), Idenix SARL, a [corporation] organized under the laws of France ("*Idenix France*"), Idenix (Cayman) Limited, a company organized under the laws of the Cayman Islands ("*Idenix Cayman*"), the Università degli studi di Cagliari, a university organized under the laws of Italy ("*University of Cagliari*"), the Centre National De La Recherche Scientifique, a [corporation] organized under the laws of France ("*CNRS*"), and L'Université Montpellier II, a [public institution] organized under the laws of France ("*UM II*"). (Idenix USA, Idenix France, Idenix Cayman, University of Cagliari, CNRS and UM II also may be referred to herein individually as a "*party*" and collectively as the "*parties*.")

RECITALS

A. Idenix France, on behalf of itself and Idenix USA, and CNRS and UM II are parties to that certain Restated and Amended Cooperative Joint Research Agreement dated as of May 7, 2003 (the "*French Joint Research Agreement*"), pursuant to which each of the parties thereto agreed to jointly own all "Results" (as defined therein) and patents covering such Results.

B. Idenix France, through its predecessor Novirio SARL, and the University of Cagliari are parties to that certain Co-Operative Antiviral Research Activity Agreement dated January 4, 1999, as amended (the "*Italian Joint Research Agreement*"), pursuant to which each of them have agreed to jointly own all results obtained from the activities taken thereunder and patents covering such results.

C. Idenix France, through its predecessor Novirio SARL, and Idenix Cayman, through its contributor Novirio Pharmaceuticals Limited, a corporation formerly organized under the laws of the Cayman Islands, are parties to that certain Research and Development Agreement dated as of August 24, 1998 pursuant to which Idenix Cayman owns all intellectual property rights developed pursuant to "Projects" (as defined therein), except certain of such rights owned by Idenix USA.

D. The inventors of the United States and foreign patents and patent applications listed on Attachment A assigned their individual rights, titles and interests to their respective employers before the Effective Date.

E. The parties desire that each of Idenix USA, University of Cagliari, CNRS and UM II (collectively, the "*Joint Assignees*") each jointly own an equal, undivided right, title and interest in the Jointly Owned Patents (as defined below), subject to the rights and obligations of each Joint Assignee with respect thereto set forth in the French Joint Research Agreement or the Italian Joint Research Agreement, as applicable, through partial assignments by the respective owners as of the Effective Date as necessary to accurately document and record such agreement.

AGREEMENT

NOW, THEREFORE, for good and valuable consideration (including the premises and covenants set forth in the Italian Joint Research Agreement and the French Joint Research Agreement), the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

Each of the parties (each an "*Assignor*") hereby irrevocably assigns, transfers and sets over to the Joint Assignees all or such portion of such Assignor's right, title and interest in and to the patents and patent applications listed on Attachment A (if any), together with any foreign counterparts or equivalents thereto, existing now or in the future and including, but not limited to, patents of utility, improvement or addition, utility model and appearance and industrial design patents and inventors certificates, as well as divisionals, reissues, continuations (in whole or in part), renewals and extensions of any of the foregoing and any patents that may issue from any of the foregoing or any reissues or reexaminations thereof, and including the inventions described or claimed in the foregoing (all of the foregoing, collectively, "*Jointly Owned Patents*"), for each Joint Assignee's use and enjoyment, and for the use and enjoyment of their respective successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by each Assignor if this assignment had not been made, in each case such that all of the Joint Assignees hereby jointly own an equal, undivided right, title and interest to all of the Jointly Owned Patents, subject to the terms and conditions of the French Joint Research Agreement and Italian Joint Research Agreement, as applicable.

Each Assignor authorizes and requests the United States Commissioner of Patents and Trademarks and any other similar government authority to record each Joint Assignee as a joint owner of the Jointly Owned Patents and issue any and all patents issued thereon to the Joint Assignees jointly, as assignees collectively of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of the Joint Assignees jointly and their respective successors, assigns or other legal representatives.

Assignors shall provide the Joint Assignees and their respective successors, assigns or other legal representatives, reasonable cooperation and assistance, including the execution and delivery of any and all affidavits, declarations, oaths, exhibits, assignments, powers of attorney or other documentation, as may be reasonably required in the implementation, recordation or perfection of this Assignment. Each of the parties hereby irrevocably appoints Idenix USA and its successors, assigns and other legal representatives as the true and lawful attorney-in-fact on Assignor's and Joint Assignee's behalf and in Assignor's and/or Joint Assignee's name, place and stead, to execute any further documents or instruments and do any and all further acts that may be deemed appropriate by Idenix USA and its successors, assigns and other legal representatives to effect the assignments to the Joint Assignees and their respective successors, assigns and other legal representatives, of the rights, titles and interests made hereby, and to enable such assignments to be recorded and/or perfected in the United States and all foreign countries, and to maintain, issue or extend any Jointly Owned Patents.

Each party is solely responsible for its costs and expenses associated with the execution and delivery of this Assignment. Each Joint Assignee shall be responsible for 25% of all of the out of pocket costs and expenses actually incurred by Idenix USA in connection with the recording or other perfection of this Assignment within the United States and all foreign

countries, including, but not limited to, any recording fees, taxes or other charges payable to any governmental authority or local attorney/agent in connection therewith.

This Assignment may be executed in one or more counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same instrument. This Assignment is governed by the laws of the State of Delaware.

<signature pages follow>

IN WITNESS WHEREOF, each of the parties have executed and delivered this Assignment to effective as of the Effective Date.


Idenix Pharmaceuticals, Inc.

By: 


Name: Steven A. Pierre Senior Director

Title: Chief Executive Officer

Idenix SARL

By: 
Name: Jean-Pierre Simon-Dubois
Title: Director

Idenix (Cayman) Limited

By: 
Name: Jean-Pierre Souffrin
Title: Director

By: [Gordon L. Goss](#)

Name: PA SQUALE MISTRETTA

Title: Rector

(Pasquale Mistretta)

1 (Pasquale Mistretta

Handwritten: *Handwritten*

CAGLIARI, 01 APR. 2009



**Centre National Del La Recherche
Scientifique**

By: _____ Directeur de la Politique Industrielle

Name: _____

Title: _____

Marc J. LEDOUX



L'Université Montpellier II



By: _____

Name: M^{me} Danielle Hérin

Title: Présidente

Attachment A
Jointly Owned Patents

(See attached.)

Attachment A for Patent Assignment Agreement

Jones Day CAM	Docket No.	Index Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
IDX 1017 Patent Family							
417451-999016	11874-016-888	1017 US PROV	PROV	Gosselin, G. Sommadossi, J.-P. Moussa, A. Pierra, C. Benzaitia-Priat, S. Dushan, D. La Colla, P.	60092,351	6/28/02	2' and 3' Nucleoside Prodrugs for Treating Hepatitis C Virus
417451-999016	11874-016-999	1017 US	11874-015-888 11874-016-888 11874-130-888	La Colla, P. Sommadossi, J.-P. Gosselin, G. Storer, R.	10009,296	6/27/03	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999047	11874-037-999	1017 US CON 1	CON of 11874-016-999	Gosselin, G. Storer, R. La Colla, P. Sommadossi, J.-P.	11005,471	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999048	11874-038-999	1017 US CON 2	CON of 11874-016-999	Gosselin, G. La Colla, P. Sommadossi, J.-P.	11005,442	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999049	11874-039-999	1017 US CON 3	CON of 11874-016-999	Gosselin, G. La Colla, P. Sommadossi, J.-P.	11005,466	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999050	11874-039-999	1017 US CON 4	CON of 11874-016-999	Gosselin, G. La Colla, P. Sommadossi, J.-P.	11005,440	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999051	11874-031-999	1017 US CON 5	CON of 11874-016-999	Gosselin, G. La Colla, P. Sommadossi, J.-P.	11005,443	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999052	11874-032-999	1017 US CON 6	CON of 11874-016-999	Gosselin, G. La Colla, P. Sommadossi, J.-P.	11005,446	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999053	11874-033-999	1017 US CON 7	CON of 11874-016-999	Gosselin, G. La Colla, P. Sommadossi, J.-P.	11005,472	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections

<u>Jones Day CAM</u>	<u>Docket No.</u>	<u>Identifi Ref. No.</u>	<u>Type Relat/ Country</u>	<u>Inventor</u>	<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
417451-000054	11874-034-099	1017 US CON 8	CON of 11874-016-999	Gosselin, G. LaColla, A. Sommadossi, J.-P.	11805-444	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-001016	11874-016-001	1017 CA	Canada	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	2,490,200	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-007016	11874-016-007	1017 AU	Australia	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	200263412	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-008016	11874-016-008	1017 NZ	New Zealand	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	337250	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-009016	11874-016-009	1017 MX	Mexico	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	PAT/2004/013779	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-010016	11874-016-010	1017 CL	Chile	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	1336-2003	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-011016	11874-016-011	1017 PE	Peru	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	660-2003	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-012016	11874-016-012	1017 JP	Japan	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	7664-517162	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-013016	11874-016-013	1017 NO	Norway	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	20050466	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-019016	11874-016-019	1017 RU	Russian Fed.	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	2005102096	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections

1A1285313-1
3/4/2009

Jones Day CAM	Docket No.	Ident. Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-025016	11874-016-023	1017 HK	Hong Kong	Sommadoss, J.-P. LaColla, P. Storer, R. Gosselin, G.	05100836.0	8/9/05	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-025016	11874-016-025	1017 VE	Venezuela	Sommadoss, J.-P. LaColla, P. Storer, R. Gosselin, G.	1160-2003	6/30/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-0306016	11874-016-036	1017 AR	Argentina	Storer, R. Gosselin, G. Imbach, J. L. Sommadoss, J.-P. Moussa, A.	P030102365	6/30/03	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-0307016	11874-016-037	1017 BR	Brazil	Sommadoss, J.-P. LaColla, P. Storer, R. Gosselin, G.	P0312271-9	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-0309016	11874-016-039	1017 PY	Paraguay	Sommadoss, J.-P. LaColla, P. Storer, R. Gosselin, G.	159602003	6/27/09	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-0406016	11874-016-040	1017 UY	Uruguay	Sommadoss, J.-P. LaColla, P. Storer, R. Gosselin, G.	27.816	6/30/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-041016	11874-016-041	1017 BO	Bolivia	Sommadoss, J.-P. LaColla, P. Storer, R. Gosselin, G.	SP-151-03 (SP23015)	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-055016	11874-016-055	1017 SG	Singapore	Sommadoss, J.-P. LaColla, P. Storer, R. Gosselin, G.	200407794-7	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-058016	11874-016-058	1017 IN	India	Sommadoss, J.-P. LaColla, P. Storer, R. Gosselin, G.	341/RELNP/2005	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections

<u>Jones Day CAM</u>	<u>Docket No.</u>	<u>Index Ref. No.</u>	<u>Type Related/ Country</u>	<u>Inventor</u>	<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
417451-074016	11874-016-076	1017 ID	Indonesia	Sommadossi, J.-P. LaCaila, P. Storer, R. Gosselin, G.	W002000000 216	62706	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-074016	11874-016-073	1017 EG	Egypt	Sommadossi, J.-P. LaCaila, P. Storer, R. Gosselin, G.	6170003	62803	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-106016	11874-016-106	1017 MA	Morocco	Sommadossi, J.-P. LaCaila, P. Storer, R. Gosselin, G.	28072	62703	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-117016	11874-016-117	1017 PH	Philippines	Sommadossi, J.-P. LaCaila, P. Storer, R. Gosselin, G.	1-2007- 500175	62703	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-131016	11874-016-131	1017 TH	Thailand	Sommadossi, J.-P. LaCaila, P. Storer, R. Gosselin, G.	083423	62703	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-146016	11874-016-146	1017 CN	China	Sommadossi, J.-P. LaCaila, P. Storer, R. Gosselin, G.	0300690.0	62703	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-147016	11874-016-147	1017 ZA	South Africa	Sommadossi, J.-P. LaCaila, P. Storer, R. Gosselin, G.	2004/10289	62703	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-150016	11874-016-150	1017 PL	Poland	Sommadossi, J.-P. LaCaila, P. Storer, R. Gosselin, G.	P374992	62703	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-154016	11874-016-154	1017 YU	Yugoslavia (former)	Sommadossi, J.-P. LaCaila, P. Storer, R. Gosselin, G.	P-141404	62703	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections

<u>Jones Day CAM</u>	<u>Docket No.</u>	<u>Index Ref. No.</u>	<u>Type Related/ Country</u>	<u>Inventor</u>	<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
417451-154016	11874-016-138	1017 IL	Israel	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	165891	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-178016	11874-016-178	1017 PK	Pakistan	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	5762003	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-185016	11874-016-185	1017 TW	Taiwan	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	92117542	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-187016	11874-016-187	1017 KR	South Korea	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	162004- 702137	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-189016	11874-016-189	1017 VN	Vietnam	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	172005- 00109	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-214016	11874-016-214	1017 OA	OAPI	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	1200400341	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-227016	11874-016-227	1017 EP	EPO	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	03761740.5	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-228016	11874-016-228	1017 WO	PCT	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	PCT/IB2003/ 009901	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
417451-241016	11874-016-241	1017 MY	Malaysia	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	P120032435	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections

Jones Day C&M	Docket No.	Identif. Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-362016	11874-016-362	1017 AP	ARIPO	Sommadossi, J.-P. LaColla, P. Storer, R. Gosselin, G.	109966003 211	6/27/03	1', 2' and 3' Modified Nucleoside Derivatives for Treating Flaviviridae Infections
IDX 1018 Patent Family							
417451-488035	11874-055-888	1018 US PROV	PROV	Storer, R. Gosselin, G. Sommadossi, J.-P. LaColla, P.	60592330	6/28/02	Modified 2' and 3' Nucleoside Prodrugs for Treating Hepatitis C Virus
417451-399055	11874-055-999	1018 US	11874-016-888 11874-055-888 11874-136-888	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	106083907	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-399056	11874-055-999	1018 US CON 1	CON of 11874-055-999	LaColla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	11005445	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-399057	11874-055-999	1018 US CON 2	CON of 11874-055-999	LaColla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	11005473	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-399058	11874-055-999	1018 US CON 3	CON of 11874-055-999	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	11005468	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-399059	11874-055-999	1018 US CON 4	CON of 11874-055-999	LaColla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	11005467	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-399060	11874-056-999	1018 US CON 5	CON of 11874-055-999	Storer, R. Gosselin, G. Sommadossi, J.-P.	11005470	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-399061	11874-061-999	1018 US CON 6	CON of 11874-055-999	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	11005447	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections

LSA 295311v1
3/4/2009

Jones Day CAM	Docket No.	Identix Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-999662	11874-062-999	1018 US CON 7	CON of 11874-055-999	Sorer, R. Gosselin, G. LaCelle, P. Sommadossi, J.-P.	11005-441	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999963	11874-063-999	1018 US CON 8	CON of 11874-055-999	LaCelle, P. Sorer, R. Gosselin, G. Sommadossi, J.-P.	11005-469	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999190	11874-190-999	1018 US DIV	DIV of 11874- 055-999	LaCelle, P. Sorer, R. Gosselin, G. Sommadossi, J.-P.	12131-868	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-001055	11874-055-011	1018 CA	Canada	LaCelle, P. Sorer, R. Gosselin, G. Sommadossi, J.-P.	2,490,191	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-007055	11874-055-007	1018 AU	Australia	Sorer, R. Gosselin, G. LaCelle, P. Sommadossi, J.-P.	2003247084	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-008055	11874-055-008	1018 NZ	New Zealand	LaCelle, P. Sorer, R. Gosselin, G. Sommadossi, J.-P.	537663	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-009055	11874-055-009	1018 MX	Mexico	LaCelle, P. Sorer, R. Gosselin, G. Sommadossi, J.-P.	PA6/00040 12709	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-010055	11874-055-010	1018 CL	Chile	Sorer, R. Gosselin, G. LaCelle, P. Sommadossi, J.-P.	1337-2003	6/30/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-011055	11874-055-011	1018 PE	Peru	LaCelle, P. Sorer, R. Gosselin, G. Sommadossi, J.-P.	006592003	6/30/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections

141-2653113-41
3/4/2009

<u>Jones Day CAM</u>	<u>Docket No.</u>	<u>Index Ref. No.</u>	<u>Type Related/ Country</u>	<u>Inventor</u>	<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
417451-012055	11874-055-012	1018 JP	Japan	LaColla, P. Storer, R. Grosselin, G. Sommadossi, J.-P.	2004- 511158	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-015605	11874-055-015	1018 NO	Norway	Storer, R. Grosselin, G. LaColla, P. Sommadossi, J.-P.	20050465	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-019605	11874-055-019	1018 RU	Russian Fed.	Storer, R. Grosselin, G. LaColla, P. Sommadossi, J.-P.	2005102013	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-022055	11874-055-023	1018 HK	Hong Kong	LaColla, P. Storer, R. Grosselin, G. Sommadossi, J.-P.	05106974.2	8/12/05	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-022055	11874-055-025	1018 VE	Venezuela	LaColla, P. Storer, R. Grosselin, G. Sommadossi, J.-P.	1101-3003	6/30/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-036605	11874-055-026	1018 AR	Argentina	Storer, R. Grosselin, G. LaColla, P. Sommadossi, J.-P.	P00102366	6/30/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-037655	11874-055-037	1018 BR	Brazil	Storer, R. Grosselin, G. LaColla, P. Sommadossi, J.-P.	P0012246-7	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-039855	11874-055-039	1018 PY	Paraguay	Storer, R. Grosselin, G. LaColla, P. Sommadossi, J.-P.	156912063	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-040255	11874-055-040	1018 UY	Uruguay	Storer, R. Grosselin, G. LaColla, P. Sommadossi, J.-P.	271875	6/30/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections

<u>Jones Day</u> <u>CAM</u>	<u>Docket No.</u>	<u>Index</u> <u>Ref. No.</u>	<u>Type</u> <u>Related/</u> <u>Country</u>	<u>Inventor</u>	<u>Serial</u> <u>No.</u>	<u>Filed</u>	<u>Title</u>
417451-041055	11874-055-041	1018 BO	Bolivia	Sorier, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	SP-190-03	6/3/003	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-055055	11874-055-055	1018 SG	Singapore	Sorier, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	200407747-5	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-056055	11874-055-056	1018 IN	India	Sorier, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	34/02ELNP/2005	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-070055	11874-055-070	1018 ID	Indonesia	Sorier, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	WO/0002000 215	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-078055	11874-055-078	1018 EG	Egypt	Sorier, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	171/2004	4/18/2004	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-106055	11874-055-106	1018 MA	Morocco	Sorier, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	20069	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-117055	11874-055-117	1018 PH	Philippines	Sorier, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	1-2004-500773	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-131055	11874-055-131	1018 TH	Thailand	Sorier, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	083424	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-146055	11874-055-146	1018 CN	China	Sorier, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	03820001.7	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections

Jones Day CAM	Docket No.	Ident Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-14055	11874-055-187	1018 ZA	South Africa	LaColla, P. Sorer, R. Gosselin, G. Sommadossi, J.-P.	2004/0249	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-150655	11874-055-150	1018 PL	Poland	LaColla, P. Sorer, R. Gosselin, G. Sommadossi, J.-P.	P-374631	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-154055	11874-055-154	1018 YU	Yugoslavia (Bosnia)	Sorer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	P-114004	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-158055	11874-055-158	1018 IL	Israel	Sorer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	164893	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-178055	11874-055-178	1018 PK	Pakistan	LaColla, P. Sorer, R. Gosselin, G. Sommadossi, J.-P.	540/2003	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-185055	11874-055-185	1018 TW	Taiwan	Sorer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	9217546	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-187055	11874-055-187	1018 KR	South Korea	LaColla, P. Sorer, R. Gosselin, G. Sommadossi, J.-P.	107504- 7021286	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-189055	11874-055-189	1018 VN	Vietnam	LaColla, P. Sorer, R. Gosselin, G. Sommadossi, J.-P.	1-2005- 00107	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-214055	11874-055-214	1018 OA	OAPI	Sorer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	120400344	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections

LA1-295313v4
3/4/2009

<u>Jones Div.</u> <u>CAM</u>	<u>Docket No.</u>	<u>Identif.</u> <u>Ref. No.</u>	<u>Type</u> <u>Related/ Country</u>	<u>Inventor</u>	<u>Serial</u> <u>No.</u>	<u>Filed</u>	<u>Title</u>
417451-227055	11874-026-999	1018 EP	EPO	La Colla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	03761744.6	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-228055	11874-026-999	1018 WO	PCT	La Colla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	PCT/IB2003/000346	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-241055	11874-026-999	1018 MY	Malaysia	Storer, R. Gosselin, G. La Colla, P. Sommadossi, J.-P.	P20032435	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-262055	11874-026-999	1018 AP	ARIPO	La Colla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	AP/P2005500312	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-146144	11874-144-146	1018 CN (D1P)	China	La Colla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	2007101933 01.0	12/3/07	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
IDX 1031 Patent Family							
417451-999026	11874-026-999	1031 US	11874-016-888 11874-136-888	Sommadossi, J.-P. La Colla, P. Gosselin, G.	104607599	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-999026	11874-026-999	1031 US CON 1	CON of 11874-026-999	Sommadossi, J.-P. Gosselin, G. La Colla, P.	11516328	9/6/06	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-001026	11874-026-001	1031 CA	Canada	Sommadossi, J.-P. La Colla, P. Gosselin, G.	2,489,552	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-001026	11874-026-007	1031 AU	Australia	Sommadossi, J.-P. La Colla, P. Gosselin, G.	2003248748	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-008026	11874-026-008	1031 NZ	New Zealand	Sommadossi, J.-P. La Colla, P. Gosselin, G.	531662	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections

Jones Day CAM	Docket No.	Identif Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-069026	11874-026-009	1031 MX	Mexico	Sommadossi, J.-P. La Colla, P. Gosselin, G.	PA/020440 12802	6/7/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-010026	11874-026-010	1031 CL	Chile	Sommadossi, J.-P. La Colla, P. Gosselin, G.	1338-2003	6/30/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-011026	11874-026-011	1031 PE	Peru	Sommadossi, J.-P. La Colla, P. Gosselin, G.	006461- 2003	6/30/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-013026	11874-026-012	1031 JP	Japan	Sommadossi, J.-P. La Colla, P. Gosselin, G.	2004 518041	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-015026	11874-026-015	1031 NO	Norway	Sommadossi, J.-P. La Colla, P. Gosselin, G.	2005/0490	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-019026	11874-026-019	1031 RU	Russian Fed	Sommadossi, J.-P. La Colla, P. Gosselin, G.	2005/02380	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-023026	11874-026-023	1031 HK	Hong Kong	Sommadossi, J.-P. La Colla, P. Gosselin, G.	05106114.3	7/1/05	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-025026	11874-026-025	1031 VE	Venezuela	Sommadossi, J.-P. La Colla, P. Gosselin, G.	1099-3003	6/30/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-036026	11874-026-026	1031 AR	Argentina	Sommadossi, J.-P. La Colla, P. Gosselin, G.	P030102363	6/30/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-037026	11874-026-037	1031 BR	Brazil	Sommadossi, J.-P. La Colla, P. Gosselin, G.	P0312278-6	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-039026	11874-026-039	1031 PY	Paraguay	Sommadossi, J.-P. La Colla, P. Gosselin, G.	15962/2003	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-040026	11874-026-040	1031 UY	Uruguay	Sommadossi, J.-P. La Colla, P. Gosselin, G.	27.874	6/30/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections

Jones Day CAM	Docket No.	Index Ref. No.	Type Related/ Country	Inventor	Serial No.	Filed	Title
417451-041026	11874-026-641	1031 BO	Bolivia	Sommadossi, J.P. La Colla, P. Gosselin, G.	SP-230049	6/3/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-053026	11874-026-035	1031 SG	Singapore	Sommadossi, J.P. La Colla, P. Gosselin, G.	700407793-9	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-056026	11874-026-036	1031 IN	India	Sommadossi, J.P. La Colla, P. Gosselin, G.	344061NP (2005)	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-076026	11874-026-076	1031 ID	Indonesia	Sommadossi, J.P. La Colla, P. Gosselin, G.	W000300500 214	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-078026	11874-026-078	1031 EG	Egypt	Sommadossi, J.P. La Colla, P. Gosselin, G.	6162503	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-106026	11874-026-106	1031 MA	Morocco	Sommadossi, J.P. La Colla, P. Gosselin, G.	28070	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-117026	11874-026-117	1031 PH	Philippines	Sommadossi, J.P. La Colla, P. Gosselin, G.	1-2006- 50012	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-131026	11874-026-131	1031 TH	Thailand	Sommadossi, J.P. La Colla, P. Gosselin, G.	08422	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-146026	11874-026-146	1031 CN	China	Sommadossi, J.P. La Colla, P. Gosselin, G.	03820701X	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-147026	11874-026-147	1031 ZA	South Africa	Sommadossi, J.P. La Colla, P. Gosselin, G.	2004/02590	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-158026	11874-026-150	1031 PL	Poland	Sommadossi, J.P. La Colla, P. Gosselin, G.	P-374781	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-158026	11874-026-154	1031 YU	Yugoslavia (former)	Sommadossi, J.P. La Colla, P. Gosselin, G.	P-113904	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections

LAU2953113v1
3/4/2009

<u>Jones Day C.A.M.</u>	<u>Docket No.</u>	<u>Identif. Ref. No.</u>	<u>Type Related/ Country</u>	<u>Inventor</u>	<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
4/7451-13026	11874-026-158	1031 IL	Israel	Sommadossi, J.P. La Colla, P. Gosselin, G.	165757	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
4/7451-118026	11874-026-178	1031 PK	Pakistan	Sommadossi, J.P. La Colla, P. Gosselin, G.	579/2003	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
4/7451-185026	11874-026-183	1031 TW	Taiwan	Sommadossi, J.P. La Colla, P. Gosselin, G.	931/1544	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
4/7451-1187026	11874-026-187	1031 KR	South Korea	Sommadossi, J.P. La Colla, P. Gosselin, G.	10-2004 7021073	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
4/7451-184026	11874-026-189	1031 VN	Vietnam	Sommadossi, J.P. La Colla, P. Gosselin, G.	1-2005 00106	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
4/7451-214026	11874-026-214	1031 OA	OAPI	Sommadossi, J.P. La Colla, P. Gosselin, G.	1200400343	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
4/7451-227026	11874-026-227	1031 EP	EPO	Sommadossi, J.P. La Colla, P. Gosselin, G.	03/62183.6	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
4/7451-228026	11874-026-228	1031 WO	PCT	Sommadossi, J.P. La Colla, P. Gosselin, G.	PCT/US2003 3020431	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
4/7451-241026	11874-026-241	1031 MY	Malaysia	Sommadossi, J.P. La Colla, P. Gosselin, G.	P10002434	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
4/7451-262026	11874-026-262	1031 AP	ARIPO	Sommadossi, J.P. La Colla, P. Gosselin, G.	497000360 00313	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
4/7451-308086	11874-086-008	1031 NZ (DIV)	New Zealand	Sommadossi, J.P. La Colla, P. Gosselin, G.	556268	7/2/07	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
4/7451-055086	11874-086-055	1031 SG (DIV)	Singapore	Sommadossi, J.P. La Colla, P. Gosselin, G.	200700644- 9	7/26/07	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections

LA1-295313-1v1
3/4/2009

<u>Jones Day CAM</u>	<u>Docket No.</u>	<u>Index Ref. No.</u>	<u>Type Related/ Country</u>	<u>Inventor</u>	<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
417451-265086	11874-086-056	1031 IN (DIV)	India	Sommadossi, L.P. La Colla, P. Gosselin, G.	8806/DELIN P/2007	11/15/07	2'-O-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-146086	11874-086-146	1031 CN (DIV)	China	Sommadossi, L.P. La Colla, P. Gosselin, G.	2000/10199 501.7	12/10/07	2'-O-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-147086	11874-086-147	1031 ZA (DIV)	South Africa	Sommadossi, L.P. La Colla, P. Gosselin, G.	2006/07218	8/29/06	2'-O-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-178086	11874-086-178	1031 PK (DIV)	Pakistan	Sommadossi, L.P. La Colla, P. Gosselin, G.	54/2007	12/20/07	2'-O-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
IDX 1040 Patent Family							
417451-488077	11874-077-488	1040 US PROV	PROV	Gosselin, G. Seetha, F. La Colla, P. Sommadossi, L.P. Dudhan, D. Leroy, F.	60/582,182	6/23/04	5-Aza-7-Deoxyuridine Derivatives for Treating Flaviviridae
417451-999077	11874-077-999	1040 US	11874-077-488	Gosselin, G. Seetha, F. La Colla, P. Sommadossi, L.P. Dudhan, D. Leroy, F.	11/166,498	6/23/05	5-Aza-7-Deoxyuridine Derivatives for Treating Flaviviridae
417451-001077	11874-077-001	1040 CA	Canada	Gosselin, G. Seetha, F. La Colla, P. Sommadossi, L.P. Dudhan, D. Leroy, F.	2,371,675	6/23/05	5-Aza-7-Deoxyuridine Derivatives for Treating Flaviviridae
417451-001077	11874-077-007	1040 AU	Australia	Gosselin, G. Seetha, F. La Colla, P. Sommadossi, L.P. Dudhan, D. Leroy, F.	2005/26963	6/23/05	5-Aza-7-Deoxyuridine Derivatives for Treating Flaviviridae

<u>Jones Day CAM</u>	<u>Docket No.</u>	<u>Index Ref. No.</u>	<u>Type Related/ Country</u>	<u>Inventor</u>	<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
417451-060077	11874-077-008	1040 NZ	New Zealand	Gosselin, G. Seetha, F. LaColla, P. Storer, R. Dushian, D. Levy, F.	553612	6/23/05	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae
417451-060077	11874-077-009	1040 MX	Mexico	Gosselin, G. Seetha, F. LaColla, P. Storer, R. Dushian, D. Levy, F.	P46/2006/015965	6/23/05	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae
417451-013077	11874-077-012	1040 JP	Japan	Gosselin, G. Seetha, F. LaColla, P. Storer, R. Dushian, D. Levy, F.	2005-517550	6/23/05	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae
417451-015077	11874-077-013	1040 NO	Norway	Gosselin, G. Seetha, F. LaColla, P. Storer, R. Dushian, D. Levy, F.	20070240	6/23/05	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae
417451-019077	11874-077-019	1040 RU	Russian Fed.	Gosselin, G. Seetha, F. LaColla, P. Storer, R. Dushian, D. Levy, F.	2007102381	6/23/05	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae
417451-033077	11874-077-037	1040 BR	Brazil	Gosselin, G. Seetha, F. LaColla, P. Storer, R. Dushian, D. Levy, F.	P4012360-7	6/23/05	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae
417451-055077	11874-077-053	1040 SG	Singapore	Gosselin, G. Seetha, F. LaColla, P. Storer, R. Dushian, D. Levy, F.	200608949-4	6/23/05	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae

LA-2953132-1
3/4/2009

<u>Jones Day CAM</u>	<u>Docket No.</u>	<u>Identif. Ref. No.</u>	<u>Type Related/ Country</u>	<u>Inventor</u>	<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
417451-056077	11874-077-056	1040 IN	India	Goudalin, G. Soria, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F.	4204 DELNP /0007	6/23/05	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae
417451-018677	11874-077-078	1040 EG	Egypt	Goudalin, G. Soria, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F.	PC1725420 06	6/23/05	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae
417451-146077	11874-077-146	1040 CN	China	Goudalin, G. Soria, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F.	2005800257 94.6	6/23/05	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae
417451-154077	11874-077-154	1040 YU	Yugoslavia (former)	Goudalin, G. Soria, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F.	P-200606684	6/23/05	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae
417451-156077	11874-077-158	1040 IL	Israel	Goudalin, G. Soria, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F.	180200	6/23/05	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae
417451-187077	11874-077-187	1040 KR	South Korea	Goudalin, G. Soria, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F.	10-2007- 7001047	6/23/05	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae
417451-227077	11874-077-227	1040 EP	EPO	Goudalin, G. Soria, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F.	0578001.7	6/23/05	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae

<u>Jones Day CAM</u>	<u>Docket No.</u>	<u>Index Ref. No.</u>	<u>Type Related/ Country</u>	<u>Inventor</u>	<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
417451-228077	11874-077-238	1040 WO	PCT	Georlin, G. Seeth, F. LaColle, P. Shorer, R. Dukhan, D. Leroy, F.	PCT/IB2005 002708	62305	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae
417451-355077	11874-077-255	1040 U.A.	Ukraine	Georlin, G. Seeth, F. LaColle, P. Shorer, R. Dukhan, D. Leroy, F.	200706649	62305	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae

141295113v1
3/4/2009